No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Bevyxxa is a hematological drug used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults who have been hospitalized for an acute medical illness. It is a direct oral anticoagulant (DOAC) that works by inhibiting the activity of thrombin, a key enzyme in the clotting process. Bevyxxa is the only DOAC approved for this indication and is the only drug approved for both DVT and PE prevention in hospitalized adults.
Bevyxxa is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2018. It is currently marketed by Portola Pharmaceuticals, Inc. in the United States and by Bayer AG in Europe. Other companies involved in the Bevyxxa market include Daiichi Sankyo, Inc., Janssen Pharmaceuticals, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. Show Less Read more
